Massachusetts

NYBC Ventures

NYBC Ventures is a Massachusetts-based life sciences specialist that backs Seed to Series B companies, with a $50M fund and investments like Akadeum and Aronora.

Entry stageSeed, Series A, Series B
Check sizen/a
Leads roundsn/a
FocusLife sciences
Latest fund$50M commitment
Investing team4 peopleNo activity since Sep

Who you would pitch at NYBC Ventures

4 people on the investing team, 3 of them partners who can make the call. Partners are listed first.

Work here and something is wrong? Ask for a correction.

Check size not reported yet.

Bars: how many firms in the atlas report each band. Highlighted: this firm.

No recent activity since September 2026. Quiet does not mean closed.

Weekly count of activity updates. Activity is not a confirmed deal.

Notable investments

AkadeumAronoraAvencellCatena BioCell OriginFunctional FluidicsImmusoftKaloCyteSTRM.BioThymmune

In their words

HomeSPECIALIZED EXPERTISEIMPACTFUL INVESTMENTS A fund accelerating breakthroughs in blood and cellulartherapies and supporting technologies NYBC Ventures elevates investment www.nybcventures.com
Founders and investors at a Mode VC gathering

Send Mode VC your deck

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.

Send your deck

Alert me when NYBC Ventures is active

One email when this firm shows new activity. Nothing else.

Firms like NYBC Ventures

On these lists

Questions

What stage does NYBC Ventures invest in?

NYBC Ventures reports entry at seed, series a, series b.

How much does NYBC Ventures invest?

NYBC Ventures has not reported a check size.

Does NYBC Ventures lead rounds?

NYBC Ventures has not reported a lead preference.

Who are the partners at NYBC Ventures?

Christopher D. Hillyer (General Partner, Manager), Meg Wood (Managing Director), Jay Mohr (General Partner, Manager).

Is NYBC Ventures active right now?

No recent activity since September 2026.

Work at NYBC Ventures? Claim or correct this profile.